SRRA

Sierra Oncology Stock Price

17.93
-0.47 (-2.55%)
Upgrade to Real-Time
Afterhours (Closed)
17.93

Low
10.02

52 Week Range

High
20.43

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Sierra Oncology Inc SRRA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.47 -2.55% 17.93 16:02:00
Open Price Low Price High Price Close Price Prev Close
18.44 17.70 18.44 17.93 18.40
Bid Price Ask Price Spread News
14.75 18.72 3.97 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
133 17,592 $ 18.28 $ 321,652 41,065 10.02 - 20.43
Last Trade Time Type Quantity Stock Price Currency
16:00:01 91 $ 18.06 USD

Sierra Oncology Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 197.96M 11.04M 3.83M $ - $ - -30.30 -1.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Sierra Oncology News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SRRA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week18.0019.0016.9417.827,237-0.07-0.39%
1 Month20.1820.4316.1019.5651,130-2.25-11.15%
3 Months16.0120.4313.6817.5534,9461.9211.99%
6 Months12.0520.4312.0216.5430,8085.8848.8%
1 Year11.5520.4310.0214.6527,8766.3855.24%
3 Years1.9820.430.201.38466,56015.95805.56%
5 Years1.5920.430.201.59453,56116.341,027.67%

Sierra Oncology Description

Sierra Oncology Inc is a clinical-stage drug development company. It focuses on the research, development, and commercialization of DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. In addition, it also engaged in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in the preclinical development stage.


Your Recent History
NASDAQ
SRRA
Sierra Onc..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.